Deep Breeze, a medical device company which provides advanced pulmonary imaging with its patented technology, is set to introduce Breeze@home telemonitoring system to evaluate lung function of chronic obstructive pulmonary disease (COPD) patients.
The Breeze home system uses Vibration Response Imaging (VRI) technology, which is based on the examination methods like auscultation, listening to chest sounds with a stethoscope.
The Breeze@home automatically transmits the collected data to the clinician via a smart phone or tablet computer.
Deep Breeze president David Barton said they have created an extremely simple interface so that the patient can activate transmission by touching just one button.
"The interface works with voice, text and video so the physician at a remote location can receive measurements and also video conference with the patient to get the full picture," Barton said.
Deep Breeze CEO Michael Nagler said measurements such as quantitative lung data, vibration energy amplitude, crackles and wheezes, and measurement and transmission of additional vital signs enables physicians to monitor and make optimal treatment decisions for their patients.
"With Breezehome company is focusing on improving health outcomes and reducing the economic burden of chronic disease to the healthcare system and the patient by aiming at early detection of exacerbations in patients with disorders like COPD and congestive heart failure (CHF), " Nagler said.
The company plans to start clinical trials in patients suffering from COPD and is currently applying for the US Food and Drug Administration approval.